Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PUMA BIOTECHNOLOGY, INC. (PBYI)
|
Add to portfolio |
|
|
|
| Price: |
$3.19
| | Metrics |
| OS: |
47.5
|
M
| |
|
|
| Market cap: |
$152
|
M
| |
|
|
|
Net debt:
|
$24.5
|
M
| |
|
|
|
EV:
|
$176
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 228.0 | 253.2 | 225.1 | 272.3 | 251.0 | 27.7 | 0.0 | 0.0 |
| Revenue growth | -9.9% | 12.5% | -17.3% | 8.5% | 806.6% | | | |
| Cost of goods sold | 55.1 | 63.7 | 39.4 | 36.8 | 34.6 | 5.6 | 0.0 | 0.0 |
| Gross profit | 172.9 | 189.5 | 185.7 | 235.4 | 216.4 | 22.1 | 0.0 | 0.0 |
| Gross margin | 75.8% | 74.8% | 82.5% | 86.5% | 86.2% | 79.9% | | |
| Selling, general and administrative | 90.0 | 116.3 | 118.5 | 141.6 | 146.2 | 106.7 | 53.8 | 31.8 |
| Research and development | 52.2 | 71.9 | 97.7 | 132.9 | 164.9 | 207.8 | 222.8 | 208.5 |
| EBITA | 38.7 | 9.3 | -24.1 | -35.1 | -90.8 | -290.8 | -276.6 | -240.3 |
| EBITA margin | 17.0% | 3.7% | -10.7% | -12.9% | -36.2% | -1050.4% | | |
| Amortization of intangibles | 8.0 | 8.0 | 6.3 | 3.9 | 3.9 | 1.6 | | |
| EBIT | 30.7 | 1.3 | -30.4 | -39.0 | -94.7 | -292.4 | -276.6 | -240.3 |
| EBIT margin | 13.5% | 0.5% | -13.5% | -14.3% | -37.7% | -1056.1% | | |
| Pre-tax income | 0.5 | -28.8 | -59.8 | -75.5 | -113.6 | -292.0 | -276.0 | -239.3 |
| Income taxes | 0.5 | 0.3 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 99.6% | | | | | 0.0% | 0.0% | 0.0% |
| Net income | 0.0 | -29.1 | -60.0 | -75.6 | -113.6 | -292.0 | -276.0 | -239.3 |
| Net margin | 0.0% | -11.5% | -26.7% | -27.8% | -45.3% | -1054.6% | | |
| |
| Diluted EPS | $0.00 | ($0.72) | ($1.52) | ($1.95) | ($2.99) | ($7.85) | ($8.29) | ($7.45) |
| Shares outstanding (diluted) | 44.9 | 40.6 | 39.6 | 38.8 | 37.9 | 37.2 | 33.3 | 32.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|